Advertisement
Organogenesis' manufacturing division has been named 2008 "Team of theYear" by Pharmaceutical Manufacturing, a prominent industry publication. The"Team of the Year" honor will be highlighted in the magazine's upcomingDecember 2008 issue. Additionally, the company was honored by theMassachusetts Alliance for Economic Development as the Silver winner of itsFifth Annual Team Massachusetts Economic Impact Award, presented at a November25th awards event.
Advertisement
Organogenesis was the first company to successfully mass produce livingregenerative medicine products -- reaching hundreds of thousands of patientsin the U.S. and around the world. Its signature product, Apligraf(R), is thefirst living cell therapy to have received U.S. Food and Drug Administration(FDA) approvals to close both diabetic foot ulcers (DFUs) and venous legulcers (VLUs).
"We are honored to receive national and state recognition of the company'svision, its ingenuity and hard work," said Geoff MacKay, CEO of Organogenesis."Organogenesis is committed to bringing the promise of regenerative medicineinto everyday medical care. To have our efforts and hard work recognized inthis way is very gratifying for the company and our employees."
MacKay continued, "The intricate processes required to mass produce aliving cell therapy product require a great deal of innovation and dedication,and our top-notch manufacturing group hits its target every day. This team isin large part responsible for the quality, the growth and the contributionthat marks Organogenesis as a regenerative medicine leader in Massachusettsand around the world."
Award Recognizes Manufacturing Excellence
Pharmaceutical Manufacturing, a national trade magazine, is honoringOrganogenesis in the small manufacturer category. PharmaceuticalManufacturing's annual award recognizes manufacturing teams in the lifesciences industry that have undertaken sizable challenges, excelled in theirwork, improved facility morale and team spirit, and achieved measurable,meaningful results. A preview of the "Team of the Year" award article isavailable online at http://www.pharmamanufacturing.com/articles/2008/161.html.
According to the publication, "The Organogenesis Apligraf ManufacturingTeam is responsible for growing Apligraf based upon a proprietary living celltechnology with a very short shelf life that requires strict attention todetail and accurate production forecasting. These challenges have defined themanufacturing team. The team has a deep sense of fulfillment from making ameaningful product. Emblematic of its award-winning commitment, the team hasfirsthand knowledge of how patients benefit, and therefore a unique emotionalconnection to the product. The team translates this connection intomanufacturing excellence."
Award Recognizes Massachusetts Economic Development Contributions
The Fifth Annual Team Massachusetts Economic Impact Award is the onlyaward of its kind in the state, honoring a select group of companies fromacross the Commonwealth recognized for their outstanding contributions to theMassachusetts economy. Organogenesis is the Silver Medal recipient for 2008.
The Team Massachusetts Economic Impact Awards honor companies in allregions of the state that have expanded the number of jobs in Massachusettsand positively contributed to their surrounding communities. According to theorganization, Organogenesis was selected because of its commitment toexpanding both its headquarters and life sciences jobs within the state.
The Massachusetts Alliance for Economic Development is a private, non-profit partnership of business, industry leaders, and government dedicated tofostering economic growth in the Commonwealth.
About Regenerative Medicine
A new frontier in healthcare, regenerative medicine utilizes living humancells to repair or replace body tissue damaged by injury, disease or even thenatural aging process.
Regenerative medicine is a multidisciplinary field which brings togetherbiology, medicine, and engineering to empower scientists to grow living cells,tissues and organs in the laboratory, and to safely implant them into thehuman body for the purposes of healing.
About Apligraf(R)
Like human skin, Apligraf contains two layers of living cells: an outer(or epidermal) layer of protective skin cells, and an inner (or dermal) layerof cells. When placed on a wound previously unresponsive to treatment,Apligraf plays an active role by providing cells and proteins that helppromote healing. In multiple controlled clinical studies, Apligraf has beenshown to be an effective and safe wound care treatment, superior toconventional treatments. It has been used to treat many thousands of patientsand is covered extensively by Medicare, Medicaid and by 350 private payers inthe U.S.
About Organogenesis, Inc.
Having pioneered the field, Massachusetts based Organogenesis, Inc. is aworld leading regenerative medicine company focused in the areas of bio-activewound healing, bio-surgery and oral regeneration. Organogenesis deliversliving tissue "on demand," and its mission is to bring the medical marvel ofregenerative medicine products to patients and to standardize their use ineveryday medical care.
The company recently established European headquarters located inSwitzerland, as well as announced an expansion of its U.S. headquarters. Formore information, visit http://www.organogenesis.com.
SOURCE Organogenesis, Inc.
